Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur Sells 5,209 Shares

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 5,209 shares of the business’s stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $4.15, for a total value of $21,617.35. Following the transaction, the chief operating officer now owns 211,041 shares in the company, valued at approximately $875,820.15. This trade represents a 2.41 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Daniel Lesueur also recently made the following trade(s):

• On Wednesday, March 5th, Daniel Lesueur sold 16,902 shares of Health Catalyst stock. The stock was sold at an average price of $4.52, for a total value of $76,397.04.
• On Wednesday, February 5th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The shares were sold at an average price of $5.76, for a total transaction of $30,003.84.

Health Catalyst Price Performance

Shares of NASDAQ HCAT opened at $3.99 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The stock has a market capitalization of $280.14 million, a price-to-earnings ratio of -2.96 and a beta of 1.43. The firm’s 50 day simple moving average is $4.85 and its 200-day simple moving average is $6.67. Health Catalyst, Inc. has a 12 month low of $3.72 and a 12 month high of $9.24.

Institutional Trading of Health Catalyst

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Group One Trading LLC grew its position in shares of Health Catalyst by 107.6% during the 4th quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock valued at $31,000 after acquiring an additional 2,260 shares during the period. Two Sigma Securities LLC grew its holdings in Health Catalyst by 19.5% in the fourth quarter. Two Sigma Securities LLC now owns 17,510 shares of the company’s stock valued at $124,000 after purchasing an additional 2,862 shares during the period. Legato Capital Management LLC increased its position in shares of Health Catalyst by 3.7% in the fourth quarter. Legato Capital Management LLC now owns 87,992 shares of the company’s stock valued at $622,000 after buying an additional 3,171 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Health Catalyst during the 4th quarter worth approximately $29,000. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Health Catalyst by 8.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 62,443 shares of the company’s stock valued at $442,000 after buying an additional 4,798 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on HCAT shares. Citigroup cut their price target on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Piper Sandler reduced their target price on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a research note on Tuesday, February 11th. Stephens dropped their price target on Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 6th. Canaccord Genuity Group reduced their price objective on Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 21st. Finally, Stifel Nicolaus dropped their target price on Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a research report on Thursday, February 27th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.27.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.